Arsenic trioxide exerts anti-lung cancer activity by inhibiting angiogenesis

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Arsenic trioxide (As2O3) is clinically used for acute promyelocytic leukemia and some solid tumors.
• Its efficacy and mechanisms against lung cancer remain largely unelucidated.
• Lung cancer remains a leading cause of cancer-related mortality worldwide.

Purpose of the Study:

• To investigate the anti-cancer effects of As2O3 on non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC).
• To elucidate the underlying mechanisms, particularly focusing on antiangiogenic properties and related signaling pathways.

Main Methods:

• Inhibition of NSCLC and SCLC xenograft tumor growth in vivo.
• Assessment of antiangiogenic effects using xenograft models and matrigel pellets.
• Evaluation of protein and gene expression of VEGF-A, VEGFR-2, HIF-1α, Dll4, and Notch-1 in tumors, cell lines, and endothelial cells.

Main Results:

• As2O3 significantly inhibited the growth of NSCLC and SCLC xenograft tumors.
• The compound demonstrated antiangiogenic effects in preclinical models.
• As2O3 downregulated the expression of VEGF-A, VEGFR-2, HIF-1α, Dll4, and Notch-1 in vitro and in vivo.

Conclusions:

• As2O3 exhibits significant anti-lung cancer activity.
• The anti-cancer effects are mediated through antiangiogenic mechanisms.
• Downregulation of VEGF and Dll4-Notch signaling pathways contributes to As2O3's efficacy in lung cancer.